Jewel Electrophysiology (EP) Lab Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-27

Study Completion Date

2024-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single arm open label evaluation of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) defibrillation waveform in adult cardiac patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm

NCT05458648

Persistent Atrial Fibrillation Cardiac Arrhythmia

COMPLETED

DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

NCT03334630

Paroxysmal Atrial Fibrillation Atrial Fibrillation

COMPLETED NA

A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)

NCT04524364

Atrial Fibrillation

COMPLETED NA

Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation

NCT04293198

Atrium; Fibrillation Ablation

COMPLETED

Parasternal Access for ShockS and Pacing With an acUtely Placed Less-invasive Lead for EV-ICD (PASS PULL EV-ICD) Study

NCT05099289

Ventricular Arrhythmia Ventricular Tachycardia Ventricular Fibrillation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to demonstrate safety and clinical effectiveness of the Jewel, using a single transthoracic defibrillation shock to terminate life-threatening VT or VF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sudden Cardiac Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Safety and Effectiveness

Group Type EXPERIMENTAL

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

Intervention Type DEVICE

Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects of both genders of at least 18 years of age.
2. Subjects who are scheduled for a standard EP clinical procedure where fast VT or VF may spontaneously occur or may be induced.

Exclusion Criteria

1. Subjects who may require sterile access to the right upper pectoral or lower left torso regions during the planned EP procedure.
2. Subjects who have taken amiodarone in the past 3 months.
3. Subjects with an existing unipolar pacemaker.
4. Subjects who exhibit a left ventricular ejection fraction (LVEF) less than 20% (as assessed by techniques such as echocardiography, magnetic resonance imaging, or radionuclide angiography) within the last 6 months.
5. Subjects who have been diagnosed with heart failure (Class IV) or experienced an acute heart failure exacerbation within the previous 30 days.
6. Subjects who exhibit unstable angina.
7. Subjects with atrial fibrillation with contraindication to anticoagulation or improper anticoagulation management.
8. Subjects who are participating in an investigational study of a drug, biologic, or device not currently approved for marketing.
9. Subjects who are allergic to or have had a known adverse reaction to medical adhesives.
10. Subjects who have active skin breakdown, erythema, or other signs of infection in the pectoral or torso regions where the study device is applied.
11. Subjects with a lower abdomen circumference of less than 68.5 cm or greater than 142 cm.
12. Females who are pregnant or breastfeeding, or planning to be pregnant in the next 12 months.
13. Subjects who cannot provide or have diminished capacity to provide informed consent.
14. Any condition that an Investigator believes would interfere with the intent of the study or is not in the best interest of the patient.
15. Any patient that according to the Declaration of Helsinki is unsuitable for enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No